KUER0%

Is AI ready to refill prescriptions? Doctors are wary of Utah’s automated program 20%

By Associated Press60%

7/6/2026, 2:11:31 PM

BS Summary: This article contains 29 faulty reasoning types, including Optimism Bias, Hasty Generalization, and Appeal to Authority, with Negativity Bias as the most egregious example at 13.1% saturation with 159 hits. Analysis detected 1,528 faulty-reasoning hits from 1,210 analyzed words, generating a BS Score of 34.6% and a BS Rank of 20% (16,416 of 20,371 articles). This article is better (less manipulative) than 80.60% of the article peer group.

A prescription refill program that quietly launched in Utah earlier this year has kicked off a big medical debate: Is artificial intelligence ready to take over tasks that, until now, could only be performed by doctors? 
The program allows Utah residents to skip the doctor’s office and get their prescriptions refilled online by an AI chatbot called Doctronic. 
It’s a seemingly simple step toward making healthcare more convenient for patients and prescribers. 
But it’s also a precedent-shattering milestone that has set off alarm bells for doctors, lawyers and public health experts. 
The pilot program has laid bare a host of questions about the role of AI in medicine, including how it should be regulated, whether doctors should be able to veto it, and what kind of safety measures are needed to protect patients. 
At the center of the debate: state and federal laws limit prescribing to licensed medical professionals. 
Proponents say those laws, which have underwritten American medicine for over 100 years, should be updated to include AI chatbots and other new technologies. 
“We have crossed a threshold in terms of giving something that is not human a medical license, whether or not we want to call it that,” said Dr. 
Eric Bressman of the University of Pennsylvania. 
AI cannot practice medicine under current laws 
Bressman and other experts say they aren't opposed to AI prescribing. 
But they say it should have to meet rigorous standards akin to human doctors, who undergo years of testing and training before being licensed to practice medicine. 
In Utah, Doctronic was able to launch thanks to a “regulatory sandbox” that allows state officials to waive laws for AI companies offering promising technology. 
The refill program is currently overseen by a five-member board of AI specialists, none of whom are doctors, who say they have implemented numerous safeguards. 
During the program's initial phase, for example, human doctors review all Doctronic refill orders. 
The company expects to soon transition to fully automated refills. 
The head of the state’s medical licensing board says he and his colleagues learned of the program when its January launch was reported in the news. 
In a March letter to the state, 11 board members called for the program to be halted, citing the risks of automatically renewing medicines that can have side effects or drug interactions. 
“We were essentially told: ‘Yes, this is going on. 
And no, you don’t have a say in it,’” said Dr. 
Alan Smith, a family physician who heads the board but said he was speaking only for himself. 
Complicating the picture is the fact that medical technology is traditionally regulated at the federal level, while medical professionals are overseen by states. 
Doctronic executives consider their AI part of the state-regulated practice of medicine. 
But the federal Food and Drug Administration is supposed to oversee AI that directly impacts medical care or decision making, a line that some experts believe Doctronic has crossed. 
Some states are clearing the way for AI in healthcare 
In an interview, Doctronic’s executives wouldn't say whether they have sought permission from the FDA. 
“Our goal here is really just to meet patients where they need healthcare,” said Dr. 
Adam Oskowitz, who co-founded the company with a tech industry entrepreneur. 
“We try not to get too deep into the weeds on the regulatory side.” 
In Utah, residents can visit a Doctronic website built for the refill program. 
After confirming their identity, the AI chatbot asks users about their prescriptions and medical history, verifying that they have a valid prescription by tapping into a national pharmacy database. 
If there are no issues, the AI can renew the prescription and send it to a local pharmacy. 
If the request requires more attention, the chatbot transfers the patient to a doctor who works for Doctronic’s telehealth service. 
Oskowitz envisions a future where many routine medical tasks, including ordering tests and analyzing results, can be offloaded to Doctronic, allowing doctors to manage thousands more patients than they can today. 
Other states are also waiving rules for AI, including Texas and Wyoming. 
Meanwhile, lawmakers in Iowa, Idaho and elsewhere have introduced legislation to formally license AI medical services. 
Many of the bills are based on a template from the nonprofit Cicero Institute, a pro-AI think tank founded by Joe Lonsdale, co-founder of the artificial intelligence software company Palantir. 
Pushback against medical AI mainly stems from the economic fears of doctors and other health workers, says Cicero’s director for health policy. 
“Whoever goes first is going to take the slings and arrows because there’s economic interests, concerns about the workforce and what that’s going to mean for jobs,” said Cicero's Adam Meier. 
Doctors see potential risks to AI prescription refills 
Smith, the medical board chair, says the risks to patients are real. 
He points out that Doctronic’s list of 190 refillable medications includes blood thinners, which can become dangerous if patients develop stomach ulcers or other conditions that cause internal bleeding. 
“Many times when I see people after six months I find that their medical history or situation has changed,” Smith said. 
“Just because something was prescribed before does not mean it’s appropriate now.” 
The American Medical Association has voiced similar concerns, warning that “prescription renewals aren’t routine checkboxes.” 
Zach Boyd, who heads Utah's AI office, said Doctronic has thus far been overly cautious, often elevating uncontroversial decisions to doctors. 
In response to safety concerns, several medications have been removed from the list eligible for refills, including a drug for irregular heartbeats. 
Utah has released some initial data on the program and Doctronic plans to publish peer-reviewed studies later this year. 
Currently, the only publication about its technology is a paper written by company scientists that was not independently reviewed. 
The study looked at whether Doctronic could correctly diagnose medical conditions based on records from 500 telehealth consultations. 
In the study, Doctronic's diagnoses matched those of human doctors 80% of the time. 
The FDA is taking a hands-off approach 
Bressman says Utah should have demanded data on prescription refills up front, not after Doctronic was up and running. 
“Mostly they're accepting the company’s word on good faith that they’re up to the task,” he said. 
The current approach to AI mirrors the haphazard medical standards of the early 20th century, Bressman says, before medical schools, medical boards and other authorities agreed on national benchmarks for training and licensing. 
National guidelines on medical technology would typically come from the FDA, but the agency has indicated it plans to take a hand-off approach, at least under the current administration. 
An FDA spokesperson said the agency has not authorized any AI chatbots but “is committed to encouraging medical innovation and helping bring promising new technologies to patients, while keeping safety at the center of every decision.” 
For now, Doctronic and other companies are likely to expand across states with different regulatory approaches. 
“Companies may benefit in the short term by expanding their business models and kind of having the technology go beyond the evidence,” says Daniel Aaron of University of Utah's law school. 
“But in the long term, I think they risk compromising public trust and fueling backlash.” 
This story was written by Mtthew Perrone of hte Associated Press 
Article reasoning-pattern comparisonThis article: 3.6%Associated Press: 2.2%KUER: 2.8%Confirmation Bias3.6%This article: 3.7%Associated Press: 0.8%KUER: 1.3%Anchoring Bias3.7%This article: 6.9%Associated Press: 3.1%KUER: 3.4%Availability Heuristic6.9%This article: 1.2%Associated Press: 0.8%KUER: 1.2%Representativeness Heuristic1.2%This article: 0.0%Associated Press: 0.6%KUER: 0.5%Hindsight Bias0.0%This article: 0.0%Associated Press: 1.1%KUER: 1.9%Overconfidence Bias0.0%This article: 7.0%Associated Press: 7.3%KUER: 7.4%Framing Effect7.0%This article: 0.0%Associated Press: 0.4%KUER: 1.3%Loss Aversion0.0%This article: 2.0%Associated Press: 0.6%KUER: 1.2%Status Quo Bias2.0%This article: 0.0%Associated Press: 0.1%KUER: 0.3%Sunk Cost Effect0.0%This article: 11.2%Associated Press: 2.1%KUER: 4.4%Optimism Bias11.2%This article: 1.2%Associated Press: 1.4%KUER: 2.4%Pessimism Bias1.2%This article: 13.1%Associated Press: 8.7%KUER: 6.3%Negativity Bias13.1%This article: 3.7%Associated Press: 2.1%KUER: 2.2%Self-Serving Bias3.7%This article: 1.8%Associated Press: 0.8%KUER: 0.9%Fundamental Attribution Error1.8%This article: 1.0%Associated Press: 0.2%KUER: 0.2%Actor-Observer Bias1.0%This article: 0.0%Associated Press: 1.1%KUER: 1.9%In-Group Bias0.0%This article: 4.5%Associated Press: 0.4%KUER: 0.6%Out-Group Homogeneity Bias4.5%This article: 0.0%Associated Press: 2.6%KUER: 2.3%Halo Effect0.0%This article: 0.0%Associated Press: 0.2%KUER: 0.1%Horn Effect0.0%This article: 0.0%Associated Press: 0.0%KUER: 0.0%Dunning-Kruger Effect0.0%This article: 4.0%Associated Press: 1.5%KUER: 1.2%Recency Bias4.0%This article: 0.0%Associated Press: 0.3%KUER: 0.3%Primacy Effect0.0%This article: 0.0%Associated Press: 0.0%KUER: 0.1%Blind-Spot Bias0.0%This article: 2.6%Associated Press: 0.8%KUER: 0.6%Ad Hominem2.6%This article: 0.0%Associated Press: 0.2%KUER: 0.4%Straw Man0.0%This article: 7.4%Associated Press: 3.5%KUER: 4.7%Appeal to Authority7.4%This article: 3.0%Associated Press: 0.8%KUER: 1.7%False Dilemma3.0%This article: 5.0%Associated Press: 0.5%KUER: 1.1%Slippery Slope5.0%This article: 0.0%Associated Press: 0.0%KUER: 0.2%Circular Reasoning0.0%This article: 9.7%Associated Press: 2.7%KUER: 4.1%Hasty Generalization9.7%This article: 0.0%Associated Press: 0.2%KUER: 0.2%Red Herring0.0%This article: 1.8%Associated Press: 0.4%KUER: 0.7%Bandwagon1.8%This article: 4.5%Associated Press: 4.6%KUER: 5.6%Appeal to Emotion4.5%This article: 0.0%Associated Press: 0.6%KUER: 0.7%Begging the Question0.0%This article: 2.7%Associated Press: 2.3%KUER: 2.4%Post Hoc (False Cause)2.7%This article: 0.0%Associated Press: 0.2%KUER: 0.1%Tu Quoque0.0%This article: 0.0%Associated Press: 0.4%KUER: 0.4%Burden of Proof0.0%This article: 0.0%Associated Press: 0.1%KUER: 0.2%Appeal to Nature0.0%This article: 0.0%Associated Press: 0.2%KUER: 0.3%Composition/Division0.0%This article: 4.1%Associated Press: 1.8%KUER: 3.1%Anecdotal4.1%This article: 0.0%Associated Press: 0.1%KUER: 0.1%No True Scotsman0.0%This article: 4.2%Associated Press: 1.3%KUER: 1.5%Ambiguity (Equivocation)4.2%This article: 0.0%Associated Press: 0.0%KUER: 0.0%Gambler’s Fallacy0.0%This article: 0.0%Associated Press: 0.0%KUER: 0.2%Middle Ground0.0%This article: 0.0%Associated Press: 0.0%KUER: 0.1%Personal Incredulity0.0%This article: 0.0%Associated Press: 0.1%KUER: 0.1%Special Pleading0.0%This article: 2.5%Associated Press: 0.2%KUER: 0.2%Genetic Fallacy2.5%This article: 5.2%Associated Press: 1.3%KUER: 0.8%Unattributed Quote5.2%This article: 2.3%Associated Press: 1.2%KUER: 0.7%Quote-first Misdirection2.3%This article: 3.3%Associated Press: 3.1%KUER: 2.2%Biased Writer Voice3.3%This article: 0.0%Associated Press: 0.7%KUER: 1.6%Indoctrination0.0%This article: 0.0%Associated Press: 0.9%KUER: 0.8%Politically Left Leaning Bias0.0%This article: 0.0%Associated Press: 0.2%KUER: 0.3%Politically Right Leaning Bias0.0%This article: 2.9%Associated Press: 0.4%KUER: 1.0%Attempt to Sell a Product or S…2.9%

1210 words analyzed.

Speakers

8speakers29%attributed speech858writer words
Voice mapSelect a segment to jump to its words
Writer's voice • 6 words • 0.0% coverageWriter's voice • 7 words • 100.0% coverageWriter's voice • 36 words • 0.0% coverageWriter's voice • 22 words • 100.0% coverageWriter's voice • 14 words • 100.0% coverageWriter's voice • 19 words • 100.0% coverageWriter's voice • 42 words • 0.0% coverageWriter's voice • 16 words • 0.0% coverageWriter's voice • 24 words • 0.0% coverageWriter's voice • 28 words • 100.0% coverageEric Bressman of the University of Pennsylvania • 7 words • 0.0% coverageWriter's voice • 7 words • 0.0% coverageEric Bressman of the University of Pennsylvania • 11 words • 0.0% coverageWriter's voice • 27 words • 0.0% coverageWriter's voice • 25 words • 0.0% coverageWriter's voice • 25 words • 0.0% coverageWriter's voice • 14 words • 0.0% coverageWriter's voice • 10 words • 0.0% coverageWriter's voice • 26 words • 0.0% coverageWriter's voice • 32 words • 0.0% coverageWriter's voice • 9 words • 100.0% coverageWriter's voice • 11 words • 100.0% coverageAlan Smith • 17 words • 0.0% coverageWriter's voice • 23 words • 0.0% coverageWriter's voice • 12 words • 0.0% coverageWriter's voice • 29 words • 0.0% coverageWriter's voice • 10 words • 0.0% coverageWriter's voice • 15 words • 0.0% coverageWriter's voice • 15 words • 100.0% coverageAdam Oskowitz • 11 words • 0.0% coverageAdam Oskowitz • 14 words • 0.0% coverageWriter's voice • 13 words • 100.0% coverageWriter's voice • 29 words • 0.0% coverageWriter's voice • 18 words • 0.0% coverageWriter's voice • 20 words • 0.0% coverageWriter's voice • 31 words • 0.0% coverageWriter's voice • 12 words • 0.0% coverageWriter's voice • 16 words • 0.0% coverageWriter's voice • 30 words • 0.0% coverageWriter's voice • 22 words • 0.0% coverageAdam Meier • 31 words • 0.0% coverageWriter's voice • 8 words • 0.0% coverageAlan Smith • 12 words • 0.0% coverageAlan Smith • 29 words • 0.0% coverageAlan Smith • 21 words • 0.0% coverageAlan Smith • 12 words • 0.0% coverageAmerican Medical Association • 15 words • 0.0% coverageZach Boyd • 21 words • 0.0% coverageWriter's voice • 22 words • 0.0% coverageWriter's voice • 19 words • 0.0% coverageWriter's voice • 19 words • 0.0% coverageWriter's voice • 18 words • 0.0% coverageWriter's voice • 14 words • 0.0% coverageWriter's voice • 7 words • 0.0% coverageEric Bressman of the University of Pennsylvania • 19 words • 0.0% coverageEric Bressman of the University of Pennsylvania • 17 words • 0.0% coverageEric Bressman of the University of Pennsylvania • 33 words • 0.0% coverageWriter's voice • 29 words • 0.0% coverageFDA • 36 words • 0.0% coverageWriter's voice • 16 words • 0.0% coverageDaniel Aaron • 31 words • 0.0% coverageDaniel Aaron • 15 words • 0.0% coverageWriter's voice • 11 words • 0.0% coverage
Selected voice

FDA

100%flagged-word coverage
36 attributed words10% of attributed speech76% writer coverage
0%5.0%10.0%Unattributed Quote-7.3 ptsWriter: 7.3%FDA: 0.0%0.0%Biased Writer Voice-4.7 ptsWriter: 4.7%FDA: 0.0%0.0%Attempt to Sell a Product -4.1 ptsWriter: 4.1%FDA: 0.0%0.0%Quote-first Misdirection-3.3 ptsWriter: 3.3%FDA: 0.0%0.0%

Attribution is sentence-level. Pattern percentages are calculated only from words assigned to that voice.

Loading…
Loading…
Loading…
Loading…

Analysis

Hover over highlighted words in the article to view the associated bias or fallacy analysis.